EGFR and non-small cell lung carcinoma: conducted a non‐randomised single‐centre study (2020–2022, 60 patients with advanced NSCLC) in which EGFR‐TKI therapy was paused after local consolidative therapy whenever ctDNA was negative; treatment was restarted or stopped according to scheduled ctDNA/CEA monitoring.